Do You have Metastatic Prostate Cancer?

Bayer is conducting a research study in men with metastatic hormone-sensitive prostate cancer. The purpose of this study is to find out if the study drug is safe and effective at keeping prostate cancer under control or slowing the growth of tumors when given in addition to androgen deprivation therapy (ADT) and docetaxel chemotherapy. To be in this study, you must, at a minimum, meet the following criteria:

• Be a male, at least 18 years old
• Be diagnosed with metastatic prostate cancer
• Be a candidate for ADT and docetaxel, and having started ADT with our without first-generation anti-androgen
• Have not been treated with chemotherapy or immunotherapy for prostate cancer
• Have not been treated with radiotherapy within two weeks of starting the study

If you are interested in learning more about this study and the requirements to participate, visit us at